搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號 規(guī)格
Recombinant Xanthomonas axonopodis pv. citri Putative regulator of ribonuclease activity (XAC2807) CSB-YP851126XAD
CSB-EP851126XAD
CSB-BP851126XAD
CSB-MP851126XAD
CSB-EP851126XAD-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xanthomonas axonopodis pv. citri N- (5'-phosphoribosyl)anthranilate isomerase (trpF) CSB-YP851127XAD
CSB-EP851127XAD
CSB-BP851127XAD
CSB-MP851127XAD
CSB-EP851127XAD-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xanthomonas axonopodis pv. citri NADH-quinone oxidoreductase subunit B (nuoB) CSB-YP851128XAD
CSB-EP851128XAD
CSB-BP851128XAD
CSB-MP851128XAD
CSB-EP851128XAD-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xanthomonas axonopodis pv. citri Polyribonucleotide nucleotidyltransferase (pnp), partial CSB-YP851129XAD
CSB-EP851129XAD
CSB-BP851129XAD
CSB-MP851129XAD
CSB-EP851129XAD-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xanthomonas axonopodis pv. citri Probable Fe (2+)-trafficking protein (XAC2554) CSB-YP851130XAD
CSB-EP851130XAD
CSB-BP851130XAD
CSB-MP851130XAD
CSB-EP851130XAD-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xanthomonas axonopodis pv. citri Glutamyl-Q tRNA (Asp) synthetase (gluQ) CSB-YP851131XAD
CSB-EP851131XAD
CSB-BP851131XAD
CSB-MP851131XAD
CSB-EP851131XAD-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xanthomonas axonopodis pv. citri Gamma-glutamyl phosphate reductase (proA) CSB-YP851133XAD
CSB-EP851133XAD
CSB-BP851133XAD
CSB-MP851133XAD
CSB-EP851133XAD-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xanthomonas axonopodis pv. citri Integration host factor subunit beta (ihfB) CSB-YP851134XAD
CSB-EP851134XAD
CSB-BP851134XAD
CSB-MP851134XAD
CSB-EP851134XAD-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xanthomonas axonopodis pv. citri UvrABC system protein C (uvrC), partial CSB-YP851135XAD
CSB-EP851135XAD
CSB-BP851135XAD
CSB-MP851135XAD
CSB-EP851135XAD-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xanthomonas axonopodis pv. citri Probable manganese transport protein MntH (mntH), partial CSB-YP851136XAD
CSB-EP851136XAD
CSB-BP851136XAD
CSB-MP851136XAD
CSB-EP851136XAD-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xanthomonas axonopodis pv. citri ATP-dependent Clp protease adapter protein ClpS (clpS) CSB-YP851137XAD
CSB-EP851137XAD
CSB-BP851137XAD
CSB-MP851137XAD
CSB-EP851137XAD-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xanthomonas axonopodis pv. citri Lysine--tRNA ligase (lysS), partial CSB-YP851138XAD
CSB-EP851138XAD
CSB-BP851138XAD
CSB-MP851138XAD
CSB-EP851138XAD-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xanthomonas axonopodis pv. citri Enolase-phosphatase E1 (mtnC) CSB-YP851139XAD
CSB-EP851139XAD
CSB-BP851139XAD
CSB-MP851139XAD
CSB-EP851139XAD-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xanthomonas axonopodis pv. citri Histidine--tRNA ligase (hisS) CSB-YP851140XAD
CSB-EP851140XAD
CSB-BP851140XAD
CSB-MP851140XAD
CSB-EP851140XAD-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xanthomonas axonopodis pv. citri 3-methyl-2-oxobutanoate hydroxymethyltransferase (panB) CSB-YP851141XAD
CSB-EP851141XAD
CSB-BP851141XAD
CSB-MP851141XAD
CSB-EP851141XAD-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xanthomonas axonopodis pv. citri Protein hfq (hfq) CSB-YP851142XAD
CSB-EP851142XAD
CSB-BP851142XAD
CSB-MP851142XAD
CSB-EP851142XAD-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xanthomonas axonopodis pv. citri Cell division protein FtsB (ftsB), partial CSB-YP851143XAD
CSB-EP851143XAD
CSB-BP851143XAD
CSB-MP851143XAD
CSB-EP851143XAD-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xanthomonas axonopodis pv. citri Imidazolonepropionase (hutI) CSB-YP851144XAD
CSB-EP851144XAD
CSB-BP851144XAD
CSB-MP851144XAD
CSB-EP851144XAD-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xanthomonas axonopodis pv. citri 50S ribosomal protein L9 (rplI) CSB-YP851145XAD
CSB-EP851145XAD
CSB-BP851145XAD
CSB-MP851145XAD
CSB-EP851145XAD-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xanthomonas axonopodis pv. citri Kynurenine 3-monooxygenase (kmo) CSB-YP851146XAD
CSB-EP851146XAD
CSB-BP851146XAD
CSB-MP851146XAD
CSB-EP851146XAD-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達載體的選擇、表達蛋白的長度(全長或部分)、是否帶標簽等。在生產(chǎn)重組蛋白時,你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實驗更有可能成功。但是如果你做了錯誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗總結(jié)出了幾個有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達載體?

表達載體是一種DNA分子,它攜帶特定的基因進入宿主細胞,并利用細胞的蛋白質(zhì)合成機制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達載體可使外源基因在宿主細胞中高效表達,經(jīng)過多年的發(fā)展,表達載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標題所示,本文主要總結(jié)了幾個有用的技巧來選擇合適的表達載體。

第三條:如何表達具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達服務(wù),您可以點擊這里獲取更多信息。注:如果您對CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價格、交貨、質(zhì)量等,您可以點擊橙色按鈕為我們在線留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>